Candesartan for Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

This study reviewed the effectiveness of candesartan for preventing migraines. Migraines are common and can severely impact daily life. Many patients struggle with current preventive treatments due to side effects or costs. Researchers looked at randomized controlled trials (RCTs) to gather evidence. They searched several databases for studies comparing candesartan to a placebo. Three RCTs with 589 participants met the criteria for analysis. The results showed that candesartan significantly reduced the number of migraine days each month. Specifically, participants taking candesartan experienced 1.13 fewer migraine days compared to those on placebo. This suggests that candesartan could be a useful option for migraine prevention. It may provide a safer and more affordable treatment for patients who do not respond well to other therapies. Overall, the findings support further exploration of candesartan as a preventive migraine treatment. Clinical relevance: This research indicates that candesartan may effectively reduce migraine frequency, offering an alternative for patients struggling with existing treatments.